Biotech firm Pulmatrix Q3 loss widens with clinical programs paused
PULM•Pulmatrix reported a Q3 loss of $0.34 per share, with all clinical development on hold as it seeks to license or monetize assets. It expects its merger with Eos SENOLYTIX to close by the end of 2026, pending final approvals.
1. Q3 results and outlook
Pulmatrix reported a Q3 loss of $0.34 per share. The company said all clinical programs are on hold while it seeks to license or monetize its assets, and that cash is expected to fund operations through the anticipated merger closing. General and administrative expenses rose due to legal and professional services for the proposed Eos SENOLYTIX merger, which Pulmatrix expects to close by the end of 2026 pending final approvals.




